Press release
Deadline on October 18th coming up in Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR)
A Deadline is coming up on October 18, 2019 in the lawsuit for certain investors in Nektar Therapeutics (NASDAQ: NKTR).
Investors who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and there are strict and short deadlines running. Deadline: October 18, 2019. NASDAQ: NKTR stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Nektar Therapeutics (NASDAQ: NKTR) common shares between February 15, 2019 and August 8, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 15, 2019 and August 8, 2019, the Defendants failed to disclose to investors, that the Company did not comply with current good manufacturing practices, that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully, that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study, that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on October 18th coming up in Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR) here
News-ID: 1846432 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for NKTR
Oncology Drugs Market Emerging Trends and Business Opportunities by 2030 | Covid …
The Business Research Company offers " Oncology Drugs Global Market Report 2020-30: Covid 19 Impact And Recovery" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by…
NK Cell Therapy Market 2020 - 2026 :Nektar Therapeutics, Innate Pharma SA, Affim …
The Global NK Cell Therapy Market Research Report Forecast 2020 - 2026 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data which enhances the understanding, scope and application…
Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: …
An investigation was annpounced concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics.
Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over…
Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR)
An investor, who purchased shares of Nektar Therapeutics (NASDAQ: NKTR), filed a lawsuit over alleged violations of Federal Securities Laws by Nektar Therapeutics.
Investors who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and for certain investors are short and strict deadlines running. Deadline: October 18, 2019. NASDAQ: NKTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
San Francisco, CA based Nektar Therapeutics develops…
Global Interleukin-2 Market - AbbVie Inc., Alkermes Plc, APT Therapeutics, Inc., …
According to a comprehensive study by KD Market Insights analyzes and forecasts the Interleukin-2 Market at both global and regional level. The report provides an analysis of 6 years, in which 2017 is the base year, 2018 as an estimated year and 2019-2023 is forecasted period. The report consists of overall market size in 2017 and its anticipated growth in further 6 years. It gives grasp about the high demanding…
Nektar Therapeutics, Senior Vice President of Biology and Preclinical Developmen …
SMi Group has announced that Johnathan Zalevsky, Senior Vice President Biology & Preclinical Development, Nektar Therapeutics will be chairing day two of the 6th annual Cancer Vaccines conference, which will be taking place on September 27th & 28th 2017.
Johnathan is an immunologist, responsible for the research portfolio at Nektar. Possessing extensive experience on the understanding of cellular and humoral immunity as it relates to vaccination technology and the purpose…
